Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Easton Pharmaceuticals's Enterprise Value is $0.00 Mil.
Easton Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.14 Mil. Therefore, Easton Pharmaceuticals's EV-to-OCF for today is 0.00.
The historical rank and industry rank for Easton Pharmaceuticals's EV-to-OCF or its related term are showing as below:
EAPH's EV-to-OCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 11.055 * Ranked among companies with meaningful EV-to-OCF only.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Easton Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Easton Pharmaceuticals's share price for today is $2.0E-5.
Easton Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easton Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Easton Pharmaceuticals's EV-to-OCF falls into.
Easton Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Easton Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easton Pharmaceuticals (EAPH) has a EV-to-OCF of 0.00 as of Aug. 11, 2026.
Is Easton Pharmaceuticals' EV-to-OCF too high?
Easton Pharmaceuticals' current EV-to-OCF is 0.00. Overall, Easton Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Easton Pharmaceuticals' EV-to-OCF compare to FPSUF and GCAN?
Easton Pharmaceuticals' EV-to-OCF of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-OCF is 11.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easton Pharmaceuticals's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easton Pharmaceuticals stock overvalued right now?
Easton Pharmaceuticals (EAPH) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. Easton Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Easton Pharmaceuticals (EAPH), the current EV-to-OCF is 0.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.
12GF Score
Get the complete analysis for EAPH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EAPH has been successfully added to your 
